Myriad Genetics, Inc.
MYGN
$4.81
-$0.34-6.60%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 824.50M | 825.30M | 832.90M | 831.30M | 837.60M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 824.50M | 825.30M | 832.90M | 831.30M | 837.60M |
| Cost of Revenue | 247.90M | 244.60M | 246.20M | 249.30M | 252.20M |
| Gross Profit | 576.60M | 580.70M | 586.70M | 582.00M | 585.40M |
| SG&A Expenses | 537.60M | 549.30M | 549.50M | 555.70M | 560.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 892.30M | 907.40M | 909.50M | 920.30M | 925.50M |
| Operating Income | -67.80M | -82.10M | -76.60M | -89.00M | -87.90M |
| Income Before Tax | -395.10M | -425.30M | -420.30M | -126.90M | -123.40M |
| Income Tax Expenses | -29.20M | -24.80M | -25.10M | -25.50M | 3.90M |
| Earnings from Continuing Operations | -365.90 | -400.50 | -395.20 | -101.40 | -127.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -365.90M | -400.50M | -395.20M | -101.40M | -127.30M |
| EBIT | -67.80M | -82.10M | -76.60M | -89.00M | -87.90M |
| EBITDA | -14.10M | -26.20M | -17.70M | -29.10M | -26.70M |
| EPS Basic | -3.95 | -4.33 | -4.28 | -1.12 | -1.40 |
| Normalized Basic EPS | -0.51 | -0.59 | -0.54 | -0.63 | -0.61 |
| EPS Diluted | -3.95 | -4.34 | -4.29 | -1.12 | -1.41 |
| Normalized Diluted EPS | -0.51 | -0.59 | -0.54 | -0.63 | -0.61 |
| Average Basic Shares Outstanding | 370.30M | 368.10M | 365.90M | 364.00M | 362.50M |
| Average Diluted Shares Outstanding | 370.30M | 368.10M | 365.90M | 364.00M | 362.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |